Drug is licensed for secondary progressive multiple sclerosis with active disease
News
EMA confirms eligibility for submission of Moderna’s COVID-19 vaccine
Primes company to submit vaccine candidate for rolling review
Bone Therapeutics showcases allogeneic cell therapy data
Data demonstrated a 90% successful lumbar vertebrae fusion rate at 24 months
J&J’s COVID-19 vaccine trial paused on safety concerns
Participant in phase III study developed unexplained illness
Redhill expands manufacturing for COVID-19 candidate
Company signs deals with two specialist pharmaceutical manufacturers
Iksuda Therapeutics exercises licensing rights from University of Goettingen
Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
RPS calls for prevention of counterfeit medicines in UK’s supply chain
In a letter to Health Secretary Matt Hancock the RPS called for urgent action
Sanofi’s Dupixent reduces severe asthma attacks in children
Biologic therapy hit primary and all key secondary endpoints in phase III
UK biotech companies raise over £1bn in record quarter
Funds raised in equity finance between June and August 2020
Bavencio, Imbruvica among latest SMC decisions
The committee accepted a number of drugs through the PACE process
BMS’ Zeposia hits the mark in ulcerative colitis
Oral S1P receptor modulator hit both primary endpoints in a phase III trial
ViiV posts positive long-term data for two-drug HIV regimen Dovato
Dovato demonstrated non-inferior efficacy compared to TAF-based regimens
Pfizer’s Ibrance flunks early breast cancer trial
Therapy failed to improve invasive disease-free survival in high-risk patients
AZ’s long-acting COVID-19 antibody moves into phase III
Two trials will involve over 6,000 participants at sites in and outside the US
London universities join forces to ramp up COVID-19 testing
Testing Alliance created to offer 20,500 extra coronavirus tests a day
